Letter to the editor: a commentary on "Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.".
作者信息
Chen Xi, Zeng Xintao, Yang Pei, Wang Decai, Wang Jianjun
机构信息
Department of Hepatobiliary Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Department of Urology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
出版信息
Int J Surg. 2025 Sep 1;111(9):6520-6521. doi: 10.1097/JS9.0000000000002684. Epub 2025 Jun 5.
Abstract
摘要
相似文献
1
Letter to the editor: a commentary on "Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.".致编辑的信：对“系统治疗联合肝动脉灌注化疗与单纯系统治疗用于肝细胞癌：一项系统评价和荟萃分析”的评论
Int J Surg. 2025 Sep 1;111(9):6520-6521. doi: 10.1097/JS9.0000000000002684. Epub 2025 Jun 5.
2
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.晚期肝细胞癌患者一线治疗的疗效与安全性：一项系统评价和网状Meta分析
Front Immunol. 2024 Sep 17;15:1430196. doi: 10.3389/fimmu.2024.1430196. eCollection 2024.
3
Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.比较肝癌根治性切除术后复发高危患者不同辅助治疗方案的疗效。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10505-10518. doi: 10.1007/s00432-023-04874-0. Epub 2023 Jun 7.
4
Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: A systematic review and meta-analysis.肝动脉灌注化疗联合奥沙利铂（HAIC-FOLFOX）加酪氨酸激酶抑制剂和免疫检查点抑制剂作为不可切除晚期肝细胞癌一线治疗的疗效和安全性：一项系统评价和荟萃分析。
Acad Radiol. 2024 Oct 8. doi: 10.1016/j.acra.2024.09.061.
5
A Contrast-Enhanced Ultrasound Cine-Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies.一种基于超声造影动态图像的深度学习模型，用于预测晚期肝细胞癌对肝动脉灌注化疗联合全身治疗的反应。
Cancer Sci. 2025 Jul;116(7):1930-1940. doi: 10.1111/cas.70089. Epub 2025 Apr 29.
6
Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.索拉非尼联合肝动脉化疗栓塞与索拉非尼单药治疗晚期肝细胞癌的系统评价和荟萃分析。
J Gastroenterol Hepatol. 2023 Apr;38(4):486-495. doi: 10.1111/jgh.16088. Epub 2023 Jan 16.
7
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗：系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
8
Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.肝动脉灌注化疗联合索拉非尼对比索拉非尼单药治疗晚期肝细胞癌的系统评价和荟萃分析。
Clin J Gastroenterol. 2023 Dec;16(6):793-802. doi: 10.1007/s12328-023-01860-4. Epub 2023 Sep 23.
9
Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma: survival outcomes and prognostic factors from a systematic review and meta-analysis.肝动脉灌注化疗在晚期肝细胞癌中的疗效：一项系统评价和荟萃分析的生存结果及预后因素
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):587-607. doi: 10.21037/hbsn-2025-115. Epub 2025 Jul 25.
10
Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials.各种辅助化疗方法预防潜在可治愈的结直肠癌肝转移的疗效：一项随机临床试验的系统评价网络荟萃分析。
Cancer Med. 2023 Feb;12(3):2238-2247. doi: 10.1002/cam4.5157. Epub 2022 Aug 22.
本文引用的文献
1
Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials.PD-1/PD-L1抑制剂联合酪氨酸激酶抑制剂作为肝细胞癌一线治疗的疗效和安全性：一项随机对照试验的荟萃分析和试验序贯分析
Front Pharmacol. 2025 Mar 24;16:1535444. doi: 10.3389/fphar.2025.1535444. eCollection 2025.
2
Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.全身治疗联合肝动脉灌注化疗栓塞术与单纯全身治疗用于肝细胞癌的疗效比较：一项系统评价与荟萃分析
Int J Surg. 2025 May 1;111(5):3494-3507. doi: 10.1097/JS9.0000000000002326.
3
Global, regional, and national temporal trends in incidence and mortality for liver cancer due to hepatitis B, 1990-2021: a decomposition and age-period-cohort analysis for the Global Burden of Disease Study 2021.1990-2021年全球、区域和国家乙型肝炎所致肝癌发病率和死亡率的时间趋势：2021年全球疾病负担研究的分解分析和年龄-时期-队列分析
Hepatol Int. 2025 Apr;19(2):368-383. doi: 10.1007/s12072-024-10765-4. Epub 2024 Dec 19.
4
Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial.阿帕替尼联合奥沙利铂和雷替曲塞肝动脉灌注化疗治疗伴有肝外转移的肝细胞癌：Ⅱ期临床试验。
Nat Commun. 2024 Oct 14;15(1):8857. doi: 10.1038/s41467-024-52700-z.
5
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.晚期肝细胞癌患者一线治疗的疗效与安全性：一项系统评价和网状Meta分析
Front Immunol. 2024 Sep 17;15:1430196. doi: 10.3389/fimmu.2024.1430196. eCollection 2024.
6
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.经动脉化疗栓塞联合仑伐替尼和 PD-1 抑制剂治疗伴有大血管侵犯的晚期肝细胞癌的疗效和安全性。
World J Surg Oncol. 2024 May 6;22(1):122. doi: 10.1186/s12957-024-03396-4.
Zotero 插件